Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Expenditures: 2012-2025

Historic Capital Expenditures for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $1.5 million.

  • Enanta Pharmaceuticals' Capital Expenditures fell 83.71% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 28.15%. This contributed to the annual value of $12.9 million for FY2025, which is 28.15% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Capital Expenditures stood at $1.5 million for Q3 2025, which was up 840.65% from $155,000 recorded in Q2 2025.
  • Enanta Pharmaceuticals' Capital Expenditures' 5-year high stood at $9.0 million during Q3 2024, with a 5-year trough of $33,000 in Q3 2021.
  • Its 3-year average for Capital Expenditures is $3.3 million, with a median of $2.2 million in 2023.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 4,254.55% in 2022, then crashed by 97.50% in 2025.
  • Enanta Pharmaceuticals' Capital Expenditures (Quarterly) stood at $363,000 in 2021, then surged by 769.42% to $3.2 million in 2022, then crashed by 75.06% to $787,000 in 2023, then soared by 1,011.18% to $8.7 million in 2024, then plummeted by 83.71% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $155,000 for Q2 2025, and $2.5 million during Q1 2025.